Get the Stockscreener App
3.18
12.37%
0.35
Pre-market:
2.95
-0.23
-7.23%
Cellectar Biosciences Inc stock is traded at $3.18, with a volume of 54.44M.
It is up +12.37% in the last 24 hours and up +24.71% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$2.83
Open:
$4.51
24h Volume:
54.44M
Relative Volume:
63.38
Market Cap:
$13.48M
Revenue:
-
Net Income/Loss:
$-21.79M
P/E Ratio:
-0.5142
EPS:
-6.1838
Net Cash Flow:
$-23.12M
1W Performance:
+24.22%
1M Performance:
+24.71%
6M Performance:
-4.79%
1Y Performance:
+1,095%
1-Day Range:
$3.11
$4.70
1-Week Range:
$2.51
$4.70
52-Week Range:
$0.23
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.18 | 12.00M | 0 | -21.79M | -23.12M | -6.1838 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Upgrade | Maxim Group | Hold → Buy |
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
View All
Cellectar Biosciences Inc Stock (CLRB) Latest News
Cellectar Biosciences Stock: $140 Million Deal Puts Iopofosine FDA Filing in Focus - TechStock²
Crude Oil Down 4%; PayPal Shares Fall After Q1 Results - Benzinga
CLRB Stock Surges 28.6% on $140M Financing and Positive Trial Data - Meyka
Cellectar Biosciences announces up to $140M financing deal; shares surge - MSN
Dow Jumps Over 300 Points; Tyson Foods Posts Upbeat Earnings - Benzinga
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia - Investing News Network
Cellectar (CLRB) Phase 2b Data Shows Durable Responses in Waldenström Macroglobulinemia - Yahoo Finance
CLRB Stock Pops As New Cancer Trial Sparks Trading Interest - StocksToTrade
Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses - Benzinga
Cellectar Biosciences raises up to $140 million in financing By Investing.com - Investing.com South Africa
CLRB Stock Jumps As New Breast Cancer Trial Begins - timothysykes.com
Cellectar reports 12-month data for WM treatment trial - Investing.com
Cellectar reports 12-month data for WM treatment trial By Investing.com - Investing.com Canada
Cancer drug posts 17.8-month responses after four 30-minute infusions - Stock Titan
Cellectar Biosciences Inc. (CLRB) has successfully completed a financing round, led by Nantahala Capital Management, LLC. - Bitget
Cellectar Biosciences raises up to $140 million in financing - Investing.com
Cellectar Biosciences stock soars 130% on $140M financing By Investing.com - Investing.com Australia
Cellectar Biosciences Reports Positive 12-Month Follow-Up - GlobeNewswire
Cellectar Biosciences stock soars 130% on $140M financing - Investing.com
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million - The Manila Times
Cellectar lines up $140M to fund cancer drug study and FDA filing - Stock Titan
MSN - MSN
Cellectar Biosciences (CLRB) price target decreased by 59.62% to 14.28 - MSN
MSN Money - MSN
Cellectar Biosciences (NASDAQ: CLRB) details governance, ownership and financings in 10-K/A - Stock Titan
CLRB Price Today: Cellectar Biosciences INC NEW Stock Price, Quote & Chart | MEXC - MEXC Exchange
CLRB (Cellectar Biosciences Inc.) reports narrower than expected Q4 2025 loss, yet shares drop nearly 3 percent.High Interest Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Cellectar to present WM treatment data at oncology meeting By Investing.com - Investing.com Australia
Cellectar to present WM treatment data at oncology meeting - Investing.com
Cellectar Biosciences, Inc. Announces Acceptance of Abstract for Presentation on Iopofosine I-131 at ASCO Annual Meeting - Quiver Quantitative
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 - marketscreener.com
Cellectar takes cancer-drug data to ASCO for patients with no approved therapy - Stock Titan
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar Biosciences (CLRB) Begins Phase 1b Trial for Triple Ne - GuruFocus
Cellectar enrolls first patient in phase 1b cancer trial By Investing.com - Investing.com South Africa
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Triple Negative Breast Cancer - National Today
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Refractory Triple Negative Breast Cancer - National Today
Cellectar enrolls first patient in phase 1b cancer trial - Investing.com
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) - The Manila Times
First patient joins Cellectar study for hard-to-treat breast cancer - Stock Titan
Cellectar Initiates Phase 1b Trial for Triple Negative Breast Cancer - Intellectia AI
Aug Summary: How volatile is Cellectar Biosciences Inc stock2026 Spike Watch & Daily Entry Point Trade Alerts - baoquankhu1.vn
Aug Mood: Can Cellectar Biosciences Inc weather a recession2026 PostEarnings & Entry Point Strategy Guides - baoquankhu1.vn
CEO Moves: Is Cellectar Biosciences Inc a top pick in the sectorIPO Watch & Weekly Top Performers Watchlists - baoquankhu1.vn
Growth Value: Will Cellectar Biosciences Inc stock benefit from M AQuarterly Investment Review & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Trading Action: Is Cellectar Biosciences Inc vulnerable to short sellersMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Buybacks Report: How does Cellectar Biosciences Inc compare to its peersQuarterly Portfolio Report & Long-Term Growth Stock Strategies - baoquankhu1.vn
Is Cellectar (CLRB) Stock Cheap at Current Price | Price at $2.68, Up 5.10%Asset Allocation - Xã Thanh Hà
Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control - Investing.com
Aug Technicals: Will Cellectar Biosciences Inc outperform during market ralliesOil Prices & Risk Managed Investment Strategies - baoquankhu1.vn
Smart Money: Is Cellectar Biosciences Inc a top pick in the sectorQuarterly Trade Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):